CardioExchange Archive

September 8th, 2014

Selections from Richard Lehman’s Literature Review: September 8th

Richard Lehman, BM, BCh, MRCGP

This week’s topics include the PARADIGM-HF trial, sham controls in medical-device trials, the efficacy of β blockers in patients with heart failure and atrial fibrillation, and more.

---

September 2nd, 2014

Low-Carb Diet Linked to Greater Weight Loss Than Low-Fat Diet

A low-carbohydrate diet is associated with greater weight reduction than a low-fat diet among obese adults, according to an Annals of Internal Medicine study. Roughly 150 obese adults who were otherwise healthy were randomized to eat either a low-fat (<30% fat) or low-carbohydrate (<40 g/day of digestible carbohydrates) diet. Participants were provided diet-specific handbooks with recipes […]

---

September 1st, 2014

Selections from Richard Lehman’s Literature Review: September 1st

Richard Lehman, BM, BCh, MRCGP

This week’s topics include aortic valve stenosis, presenting the benefits of PCI to patients, and more.

---

August 31st, 2014

Preliminary Outcomes Results For PCSK9 Inhibitor

Larry Husten, PHD

Amid a slew of new data demonstrating yet again that PCSK9 inhibitors lower LDL cholesterol—drastically and in a wide variety of different patient populations—data from one trial offers the first suggestion that the drugs may in fact improve cardiovascular outcomes. But the analysis, the authors cautioned, is a post-hoc analysis of a trial neither designed nor […]

---

August 31st, 2014

SIGNIFY Trial Provokes Sound and Fury Over Controversial Drug

Larry Husten, PHD

The already controversial drug ivabradine just got a little more controversial. The drug, which is marketed by Servier under the brand names of Corlentor and Procoralan, is available in Europe and elsewhere and is used for the treatment of heart failure and stable angina. The drug is not available in the U.S., but it is under development by Amgen for a […]

---

August 30th, 2014

ESC.14 Headquarters

wpengine

CardioExchange is dedicated to bringing you the latest from ESC.14. Check out our coverage of the conference here at CardioExchange and don’t forget to tell us what you think! News: PARADIGM-HF Establishes a New Paradigm for Heart Failure Treatment SIGNIFY Trial Provokes Sound and Fury Over Controversial Drug Preliminary Outcomes Results For PCSK9 Inhibitor New Support For […]

---

August 28th, 2014

Predicting PARADIGM-HF, or What to Expect When You’re Expecting

Larry Husten, PHD

Larry Husten analyzes the expectations surrounding the upcoming release of PARADIGM-HF and its centerpiece LCZ696 from the perspective of the medical field as well as the world of economics.

---

August 25th, 2014

Rise in Popularity of E-Cigarettes Sparks Concerns and Recommendations

Larry Husten, PHD

The recent dramatic rise in popularity of e-cigarettes threatens to reverse hard-fought progress in the war against smoking, according to a new policy statement from the American Heart Association. “E-cigarettes have caused a major shift in the tobacco-control landscape,” said the lead author of the statement, Aruni Bhatnagar, chair of cardiovascular medicine at the University of Louisville. But the […]

---

August 21st, 2014

FDA Grants Apixaban Expanded Indication for Venous Thromboembolism

Larry Husten, PHD

The FDA today approved an expanded indication for the oral anticoagulant apixaban (Eliquis, Bristol-Myers Squibb and Pfizer). Apixaban will now be indicated for the treatment of deep venous thrombosis (DVT) and pulmonary embolism (PE), and for the reduction in the risk of recurrent DVT and PE (collectively known as venous thromboembolism) after initial therapy. The supplemental new […]

---

August 21st, 2014

The Niacin Controversy: What Do You Say to Your Patient?

Harlan M. Krumholz, MD, SM

In this scenario based on the HPS2-THRIVE study, Harlan Krumholz asks, “What do you say to your patient?”

---